0001564590-21-010039.txt : 20210302 0001564590-21-010039.hdr.sgml : 20210302 20210302073051 ACCESSION NUMBER: 0001564590-21-010039 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210302 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210302 DATE AS OF CHANGE: 20210302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA, INC. CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32302 FILM NUMBER: 21701294 BUSINESS ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 BUSINESS PHONE: 609-359-3020 MAIL ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20060120 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20020520 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 8-K 1 atrs-8k_20210302.htm 8-K atrs-8k_20210302.htm
false 0001016169 0001016169 2021-03-02 2021-03-02

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2021

 

ANTARES PHARMA, INC.

(Exact name of registrant specified in its charter)

 

 

Delaware

 

1-32302

 

41-1350192

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 

 

 

 

100 Princeton South, Suite 300, Ewing, NJ

 

08628

(Address of Principal Executive Offices)

 

(Zip Code)

(609) 359-3020

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

ATRS

 

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).  

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

 

On March 2, 2021, Antares Pharma, Inc. (the “Company”) issued a press release announcing its operating and financial results for the fourth quarter and year ended December 31, 2020. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

 

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific references in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

  

Description

 

 

99.1

  

Press Release issued by Antares Pharma, Inc., dated March 2, 2021

 

104

 

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

ANTARES PHARMA, INC.

 

 

 

 

 

Date:

 

March 2, 2021

 

By:

 

/s/ Fred M. Powell

 

 

 

 

Name:

 

Fred M. Powell

 

 

 

 

Title:

 

Executive Vice President and Chief Financial Officer

 

 

 

 EX-99.1 2 atrs-ex991_6.htm EX-99.1 atrs-ex991_6.htm

EX 99.1

    

 

  

 

 

 

 

ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2020 FINANCIAL AND OPERATING RESULTS

 

Full-Year 2020 Revenue Increases 21% Year-Over-Year to $149.6 Million

 

Full-Year 2020 Net Income Before Income Taxes of $9.9 Million, or $0.06 per Share

 

Full-Year 2020 Net Income of $56.2 Million, including a Net Tax Benefit of $46.3 million

 

EWING, NJ, March 2, 2021 – Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2020 with record revenue of $44.1 million and net income of $51.4 million, or basic and diluted earnings per share of $0.31 and $0.30, respectively, which included a net tax benefit of $46.3 million. The Company also reported record full-year 2020 revenue of $149.6 million and net income of $56.2 million, or basic and diluted earnings per share of $0.34 and $0.33, respectively. The full year net income included the above referenced net tax benefit of $46.3 million or $0.28 and $0.27 per basic and diluted share, respectively, resulting from a deferred tax asset valuation allowance reversal.  (See Table 3 for details of the components of net income and computation of per share amounts.)

 

Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, “We are very proud of our accomplishments this past year that contributed to record annual revenue of $150 million. Despite ongoing challenges due to the global COVID-19 pandemic, the diversification of our business with our proprietary and partner revenue continues to bolster our overall growth, profitability, and cash flow. Driven by strong demand for XYOSTED, our proprietary revenue grew to $63 million in 2020. The reach of our commercial sales organization to urologists and endocrinologists has continued to drive the success of XYOSTED as well as support the expansion of our proprietary portfolio with NOCDURNA. We look forward to further expanding our internal pipeline as we advance our endocrinology and urology assets from successful Pre-IND meetings with the FDA last year to IND submissions this year. Our partner business also had another strong year with total revenue of $87 million driven in large part to the significant increases in market share of Teva’s generic EpiPen.”

 

“As we look ahead, our full-year 2021 revenue guidance of $175-200 million, which represents 17% to 34% year-over-year growth, anticipates continued growth in XYOSTED as well as our partner products. We also remain excited about the potential FDA approval of Teva’s generic Forteo, ongoing progress for Pfizer’s undisclosed asset, and the initiation of Idorsia’s Phase III trial for their selatogrel rescue pen program that has received fast-track designation by the FDA. Overall, the diversification of our business has proven to be a strong foundation from which we will continue to expand.”

 

Fourth Quarter 2020 and Recent Highlights

 

 

▪

XYOSTED® total prescriptions in the fourth quarter 2020 increased 13% sequentially and 76% year-over-year, according to IQVIA.

 

 

▪

Entered an exclusive license agreement with Ferring Pharmaceuticals for NOCDURNA® in the U.S. that expands our proprietary portfolio and leverages our commercial organization.

 

 

▪

Recorded an income tax benefit of $46.3 million for the fourth quarter and full-year 2020 resulting primarily from the net valuation allowance release of $53.4 million on deferred tax assets.

 

 

 

 

 

▪

Announced full-year 2021 revenue guidance of $175-200 million, which represents a 17% to 34% year-over-year growth rate and assumes a range of revenue scenarios for the potential approval and launch of generic Forteo® by our partner Teva in the U.S.

 

Fourth Quarter and Full-Year 2020 Financial Results

 

Total revenue generated from product sales, license and development activities and royalties was $44.1 million for the three months ended December 31, 2020, a 17% increase compared to $37.8 million in the same period in 2019.  For the full year ended December 31, 2020, total revenue was $149.6 million, a 21% increase from $123.9 million for the comparable period in 2019.

Product sales were $33.1 million for the three months ended December 31, 2020, a 16% increase compared to $28.5 million for the same period in 2019.  For the twelve-month period ended December 31, 2020, product sales were $113.8 million, a 24% increase from $92.1 million in the comparable period in 2019.   

Sales of our proprietary products XYOSTED®, OTREXUP® and NOCDURNA® generated revenue of $19.7 million and $62.9 million for the three months and full-year ended December 31, 2020, respectively, as compared to $14.0 million and $39.2 million for the three months and full-year ended December 31, 2019, respectively. The 41% and 60% increase in proprietary product sales for the three-month and full-year ended December 31, 2020 respectively, compared to the three months and full-year ended December 31, 2019 were principally attributable to continued growth in prescriptions and sales of XYOSTED®.  

Partnered product sales were $13.4 million and $14.5 million for the three months ended December 31, 2020 and 2019, respectively, and $51.0 million and $52.9 million for the full year ended December 31, 2020 and 2019, respectively. The net decrease in sales of partnered products for the fourth quarter and full-year ended December 31, 2020 as compared to the same periods in 2019 is attributable to decreased sales of needle-free devices to Ferring, a decrease in sales of Makena® auto injectors to AMAG and a reduction in pre-launch quantities of generic teriparatide devices sold to Teva in previous periods.  These decreases were offset by an increase in sales to Teva of their generic EpiPen auto-injectors.

 

Licensing and development revenue was $5.7 million and $14.5 million for the three and twelve-month periods ended December 31, 2020, respectively, as compared to $3.2 million and $7.5 million for the comparable periods in 2019, respectively. The increase in licensing and development revenue for the fourth quarter and full year ended December 31, 2020 was primarily from the Pfizer rescue pen and the Idorsia selatogrel pen development programs.

 

Royalty revenue was $5.3 million for the three months ended December 31, 2020 compared to $6.2 million for the same period in 2019.  For the twelve-month period ended December 31, 2020, royalty revenue was $21.3 million, as compared to $24.2 million for the same period in 2019.  The net decrease in royalty revenue was primarily attributable to a decline in royalties recognized from AMAG on their net sales of the Makena® subcutaneous auto injectors offset by an increase in royalties from Teva on their net sales of generic EpiPen.

 

Research and development expenses were $2.3 million and $10.1 million for the three and twelve-month periods ended December 31, 2020, respectively, as compared to $2.9 million and $10.6 million for the comparable periods in 2019, respectively. The decrease in research and development costs incurred in 2020 as compared to 2019 was due to the timing of clinical studies for our internal pipeline products.

 

Selling, general and administrative expenses were $16.7 million and $62.8 million for the three and twelve-month periods ended December 31, 2020, respectively, as compared to $15.4 million and $61.8 million for the comparable periods in 2019, respectively. The net increase in selling, general and administrative expenses for the three and twelve-month period ended December 31, 2020 was

2 of 7

 

 

 

primarily due to increases in payroll and equity-based compensation costs and additional overhead costs of our new facility, offset by reductions in sales and marketing costs incurred as a result of the various stay at home orders and travel restrictions related to the COVID-19 pandemic.

 

Antares recorded an income tax benefit of $46.3 million for the fourth quarter and full-year 2020 resulting primarily from the net valuation allowance release of $53.4 million on our deferred tax assets. As of December 31, 2020, management concluded that as a result of generating pre-tax earnings, utilization of net operating loss carryovers and future projected pre-tax earnings, it is more likely than not that nearly all of our deferred taxes are realizable and may be utilized to offset future tax liabilities.

 

Including the tax benefit, net income was $51.4 million, or $0.31 and $0.30 per basic and diluted share, respectively, for the fourth quarter of 2020, compared to $4.7 million, or $0.03 per basic and diluted share in the same period in 2019.  Net income was $56.2 million, or $0.34 and $0.33 per basic and diluted share, respectively, for the full year ended December 31, 2020 compared to a net loss of $2.0 million, or $0.01 loss per basic and diluted share in the comparable period of 2019.  

 

As of December 31, 2020, cash and cash equivalents were $53.1 million compared to $45.7 million as of December 31, 2019. Cash generated from operations was $21.3 million for the full-year ended December 31, 2020, compared to cash used in operations of $10.6 million for the full-year ended December 31, 2019.

 

 

Full-Year 2021 Financial Guidance

 

The Company today reaffirmed full-year 2021 revenue guidance in the range of $175-200 million, which represents a 17% to 34% year-over-year growth rate and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic and a range of revenue scenarios for the potential approval and launch of generic Forteo® by our partner Teva in the U.S.

 

 

Webcast and Conference Call Information

 

The Antares management team will provide a Company update and review the fourth quarter and full-year 2020 financial results via conference call and webcast today, March 2, 2021, at 8:30am ET (Eastern Time).  The webcast of the conference call will include a slide presentation, which can be accessed in the investor relations section of the Company’s website (www.antarespharma.com) under “Webcasts & Presentations”.  Alternatively, callers may participate in the audio portion of the conference call by dialing (888) 254-3590 for domestic callers and (323) 994-2093 for international callers.  Callers should reference the Antares Pharma conference call or conference ID number 1389407.

 

About Antares Pharma

 

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

 


3 of 7

 

 

 

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

 

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: the Company’s ability to achieve the 2021 full-year revenue guidance; the uncertainty regarding the ongoing COVID-19 pandemic, including new strains of the virus, and the mitigation measures and other restrictions implemented in response to the same and the impact on demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; commercial success of XYOSTED® and future revenue from the same; market acceptance of Teva’s generic epinephrine auto-injector product and future revenue from the same; successful commercialization of NOCDURNA® in the United States and market acceptance and future revenue from the same; whether the FDA will withdraw marketing approval for AMAG Pharmaceuticals’ Makena® subcutaneous auto injector following the recent FDA letter seeking withdrawal, whether AMAG will be granted an appeal hearing and if granted, whether  Makena® will be successful and future prescriptions, market acceptance and revenue from the same; Teva’s ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; future prescriptions and sales of OTREXUP®; Teva’s ability to successfully commercialize generic teriparatide in 11 countries in Europe, Canada and Israel and future revenue from the same, successful development including the timing and results of the Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; FDA approval of Teva’s pending ANDA for generic Forteo® and future revenue from the same; the timing and results of the Company’s or its partners’ research projects or clinical trials of product candidates in development including the Company’s endocrinology and urology assets in development as well as Pfizer’s undisclosed development product;  actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital;  the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

 

Contact:

Tram Bui

Vice President, Corporate Communications and Investor Relations

4 of 7

 

 

 

609-359-3016

tbui@antarespharma.com

 

 

 

TABLES FOLLOW


5 of 7

 

 

 

ANTARES PHARMA, INC.

Table 1 - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(amounts in thousands except per share amounts)

(unaudited)

 

 

 

 

For the Quarter Ended

 

 

 

 

 

 

For the Year Ended

 

 

 

 

 

 

 

December 31,

 

 

Increase

 

 

December 31,

 

 

Increase

 

 

 

2020

 

 

2019

 

 

(Decrease)

 

 

2020

 

 

2019

 

 

(Decrease)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

$

33,125

 

 

$

28,496

 

 

16%

 

 

$

113,834

 

 

$

92,103

 

 

24%

 

Development and licensing revenue

 

 

5,703

 

 

 

3,164

 

 

80%

 

 

 

14,466

 

 

 

7,529

 

 

92%

 

Royalties

 

 

5,305

 

 

 

6,179

 

 

(14)%

 

 

 

21,299

 

 

 

24,232

 

 

(12)%

 

Total revenue

 

 

44,133

 

 

 

37,839

 

 

17%

 

 

 

149,599

 

 

 

123,864

 

 

21%

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales

 

 

15,404

 

 

 

12,476

 

 

23%

 

 

 

53,960

 

 

 

46,267

 

 

17%

 

Cost of development revenue

 

 

3,655

 

 

 

1,550

 

 

136%

 

 

 

9,140

 

 

 

4,208

 

 

117%

 

Research and development

 

 

2,318

 

 

 

2,880

 

 

(20)%

 

 

 

10,121

 

 

 

10,624

 

 

(5)%

 

Selling, general and administrative

 

 

16,658

 

 

 

15,366

 

 

8%

 

 

 

62,759

 

 

 

61,773

 

 

2%

 

Total operating expenses

 

 

38,035

 

 

 

32,272

 

 

18%

 

 

 

135,980

 

 

 

122,872

 

 

11%

 

Operating income

 

 

6,098

 

 

 

5,567

 

 

10%

 

 

 

13,619

 

 

 

992

 

 

1273%

 

Other expense

 

 

(992

)

 

 

(872

)

 

14%

 

 

 

(3,698

)

 

 

(3,019

)

 

22%

 

Net income (loss) before income taxes

 

 

5,106

 

 

 

4,695

 

 

9%

 

 

 

9,921

 

 

 

(2,027

)

 

**

 

Income tax benefit

 

 

46,280

 

 

 

—

 

 

**

 

 

 

46,280

 

 

 

—

 

 

**

 

Net income (loss)

 

$

51,386

 

 

$

4,695

 

 

994%

 

 

$

56,201

 

 

$

(2,027

)

 

**

 

Net income (loss) per common share, basic

 

$

0.31

 

 

$

0.03

 

 

 

 

 

 

$

0.34

 

 

$

(0.01

)

 

 

 

 

Net income (loss) per common share, diluted

 

$

0.30

 

 

$

0.03

 

 

 

 

 

 

$

0.33

 

 

$

(0.01

)

 

 

 

 

Basic weighted average common shares outstanding

 

 

166,744

 

 

 

163,952

 

 

 

 

 

 

 

166,066

 

 

 

162,574

 

 

 

 

 

Diluted weighted average common shares outstanding

 

 

171,412

 

 

 

171,238

 

 

 

 

 

 

 

170,155

 

 

 

162,574

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANTARES PHARMA, INC.

Table 2 – CONSOLIDATED DETAILS OF REVENUE

(amounts in thousands)

(unaudited)

 

 

 

 

Quarter Ended December 31,

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Proprietary product sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

XYOSTED®

 

$

14,399

 

 

$

8,423

 

 

$

46,549

 

 

$

20,769

 

OTREXUP®

 

 

4,442

 

 

 

5,579

 

 

 

15,468

 

 

 

18,446

 

NOCDURNA®

 

 

861

 

 

 

—

 

 

 

861

 

 

 

—

 

Total proprietary product sales

 

 

19,702

 

 

 

14,002

 

 

 

62,878

 

 

 

39,215

 

Partnered product sales

 

 

13,423

 

 

 

14,494

 

 

 

50,956

 

 

 

52,888

 

Total product sales

 

 

33,125

 

 

 

28,496

 

 

 

113,834

 

 

 

92,103

 

Development revenue

 

 

5,703

 

 

 

3,164

 

 

 

14,466

 

 

 

7,529

 

Royalties

 

 

5,305

 

 

 

6,179

 

 

 

21,299

 

 

 

24,232

 

Total revenue

 

$

44,133

 

 

$

37,839

 

 

$

149,599

 

 

$

123,864

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


6 of 7

 

 

 

ANTARES PHARMA, INC.

Table 3 – COMPONENTS OF NET INCOME (LOSS) AND COMPUTATION OF PER SHARE AMOUNTS

(amounts in thousands)

(unaudited)

 

 

 

 

Quarter Ended December 31,

 

 

Year Ended December 31,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Net income (loss) before income taxes

 

$

5,106

 

 

$

4,695

 

 

$

9,921

 

 

$

(2,027

)

Pre-tax earnings (loss) per share, basic and diluted

 

$

0.03

 

 

$

0.03

 

 

$

0.06

 

 

$

(0.01

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax benefit

 

$

46,280

 

 

$

—

 

 

$

46,280

 

 

$

—

 

Tax benefit per common share, basic

 

$

0.28

 

 

$

—

 

 

$

0.28

 

 

$

—

 

Tax benefit per common share, diluted

 

$

0.27

 

 

$

—

 

 

$

0.27

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

51,386

 

 

$

4,695

 

 

$

56,201

 

 

$

(2,027

)

Net income (loss) per common share, basic

 

$

0.31

 

 

$

0.03

 

 

$

0.34

 

 

$

(0.01

)

Net income (loss) per common share, diluted

 

$

0.30

 

 

$

0.03

 

 

$

0.33

 

 

$

(0.01

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic weighted average common shares outstanding

 

 

166,744

 

 

 

163,952

 

 

 

166,066

 

 

 

162,574

 

Diluted weighted average common shares outstanding

 

 

171,412

 

 

 

171,238

 

 

 

170,155

 

 

 

162,574

 

 

 

 

 

ANTARES PHARMA, INC.

Table 4 – CONSOLIDATED CONDENSED BALANCE SHEETS

(amounts in thousands)

(unaudited)

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Cash, cash equivalents and investments

 

$

53,137

 

 

$

45,721

 

Accounts receivable

 

 

42,221

 

 

 

35,074

 

Inventories

 

 

18,216

 

 

 

16,000

 

Property and equipment

 

 

24,020

 

 

 

15,961

 

Deferred tax assets

 

 

46,982

 

 

 

—

 

Goodwill and intangibles

 

 

8,788

 

 

 

1,573

 

Other assets

 

 

19,167

 

 

 

18,422

 

Total Assets

 

$

212,531

 

 

$

132,751

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

41,829

 

 

$

29,428

 

Long-term debt

 

 

40,899

 

 

 

40,395

 

Other liabilities

 

 

10,688

 

 

 

8,428

 

Stockholders’ equity

 

 

119,115

 

 

 

54,500

 

Total Liabilities and Stockholders’ Equity

 

$

212,531

 

 

$

132,751

 

 

 

 

 

7 of 7

 

 GRAPHIC 3 g05dox130o13000001.jpg GRAPHIC begin 644 g05dox130o13000001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH *0D#J<4M9>M)*T",A.T'Y@*<5=V$W97-/>O\ >'YT M;U_O#\ZXVBM_8>9G[3R.RWK_ 'A^=&]?[P_.N-HH]AYA[3R.RWK_ 'A^=&]? M[P_.N-HH]AYA[3R.RWK_ 'A^=&]?[P_.N-HH]AYA[3R.RWK_ 'A^=+7&@D'( M.#5RVU2X@(!8NOHQI.B^@U474Z:BH+6ZCNH]Z'GN/2IZP:L:!1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !2, RE6&0>HI:* .=U+3S;/YD8S$ M?TK.KLG570JPRI&"*YO4+!K63M=/;7,=U$'0_4>ET^_:UDVL''W6KFIHG@E,;C#"NJ$^9&$HV(Z***T("BBB@ HHHH **** -33-1,+"&4Y MC/0^E;X((R.0:XRM;2]2V$03-\I^ZQ[5A4IWU1K"?1F[1117.:A1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !7->)]4L[5!']^ZQP >GUJUX@U MZ/2KZB6:_N)S\TA M ]!TJ#S'_OM^=-HKO22.2['>8_\ ?;\Z/,?^^WYTVB@!WF/_ 'V_.CS'_OM^ M=-HH =YC_P!]OSH\Q_[[?G3:* '>8_\ ?;\Z4/(2 &;/;FF5MZ9IP4">8?,> M54]J4FHH:3;.I\/ZA(MI%;W;?/CAC_*NAKC.G2MS2]2W@03'YOX2>]>=5I_: M1V0ET9KT445SFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9.NZW%I%MU#7 M##Y$_J:DUG6(=)M2[D&5N$3U->:7EY-?7+SSL6=C^5=-"ASN[V,:M7ET6XRY MN9;N=IIG+.QR2:BHHKT=CC"BBBF(**** "BBB@ HHK5TS3O,(FF'RC[J^M2V MDKL:5V2:9IO2>9?]U36S1T&**YY2;=S=*R"@$@Y'4445(S?TS41,HAE/[P=# MZUJ5QJL58,#@CI70Z;J N4\N0XE'ZUS5*=M4;0G?1FC1116)H%%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 50U75(-*M&FE.6_@3NQJ34=1@TVT:>9L8^ZO=C7F6J:G/JEV MTTS<=%7LHK>A1=1W>QE5JUCB4=1ZU>KCHY&BD#H<,.AKI;"^6[BYXD'45S5*=M4;0E?1ERBBBL30*** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH *K7U[#I]JT\[;54?B:?=745G;O/,X5%&3FO-=;UJ;5[HDDK"O") M_6MJ-%U'Y&=2HH+S(]8U>;5KLRR$B,?<3L!6=117J)**LCA;;=V%%%%,0444 M4 %%%% !116QH.AR:OOL*F4E%7923D[(D\/:!)JDXEE!6V0\G^ M][5U6H:4MN@>V3$8'*CM6U;V\5K L,*A448 %2D C!&0:\V=>4I7Z'9&DE&Q MQE%:FIZ<86,T0S&>H]*RZWC)25T9M-,****8@HHHH **** "I(9G@E$B'#"H MZ* .ILKQ+N+(.''WEJU7(V\[V\HD0X(_6NFM+M+N$.O#=U]*Y:E/EU6QO"5R MQ1116184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M>&?&?QYXA\+^);2UTF]\B%X-S+M!R:W/@GXMUGQ58ZE)J]UY[0NH0[<8S7GW M[1'_ ".-C_U[?U%=+^SC_P @W6/^NB?UH ]SHHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "HYYX[:%IIG"(HR2:621(8 MVDD8*BC))[5YWXBU]]4F,,)*VR'@?WOE6EI#96R00(%11CCO3;"QATZU6"!0%' M4]R:LUY=:LZC\CNITU!>84445B:",H92K#(/45AWND.A,EN-R_W>XK=HJHS< M7H)Q3.-960X92#[BDKL'ABD^_&K?45']CM_^>*?E6WMUV,_9G)T5UGV.W_YX MI^5'V.W_ .>*?E1[==@]FSDZ*ZS[';_\\4_*C[';_P#/%/RH]NNP>S9R=%=9 M]CM_^>*?E1]CM_\ GBGY4>W78/9LY.K%G<26]PK(3R<$>M=)]CM_^>*?E3EM M8%;(B0$>U#K)K8%39(#E0?44M%%M67A_2+C4M0E$=O"N2 M3U)[ >] %]F5%+,P50,DDX K!U'QOX9THD7>LVB$=0K[_P"6:^:O'7Q"?$WB1M^GZ7<3!N?,<;5;_@38!H ^IH MOBIX*FD")KL.X^J./YBNEL=6T_4XP]C>V]P",_NY Q_*ODJ[^$/CBR@::;16 MV 9.R5'/Y YKG+:]UOPOJ"M#+=Z? M^(?QS9'FTOPN1D95[TC/_?(/^% 'M>I:[I6D1L^H:A;VX49(>0!ORZUSP^*G M@HS>5_;L._./N/C\\5\KPZ9XG\777G);W^H.Y_UKAF7_ +Z/ J>^^'GBO3H? M-N-%N=G7Y%W_ *#- 'V'INM:9K$0DT^^M[D$9Q&X)'U'45?KX7TK6=3\/:@M MSI]U-:W$;H/&T[%66)B"* .D^/]W;7 M?BZR>VN(IU%M@M$X8#D>E='^SS?V=GIVKBZNX("TB8$L@7/7UKPW4=.U#3IE MBU"VG@D(R%F4J2/QJ33M(U;4E=M.L[JX5#\QA1FQ]<4 ?;7]N:1_T%+'_P " M$_QJY%-%<1++#(DD;T MD8]%,@4G\#BMOK7P_JGAW7O#^>I'YT ?3U%1P3Q7,$<\+K)%(H964Y!%24 -=UC0N[!549+ M,< 5376M*9@JZG9%B< "X7G]:I>,"1X.U8@X/V9_Y5\9:+-+_;=C^\?_ %Z? MQ'UH ^Z*SM3U_2=&C+ZCJ%O;@=G<9_+K7GOQ0^*"^#M-ATW3MLFJSQ@Y/(A7 M'4^_I7S5=7FK>(K]I9Y+J^N7.3]YS^ [4 ?9NA^+M"\22S1Z1J"730X\P*K# M&?J*VZ\'_9\TC4=/N]7DO;&YME=4"F:)DSUZ9%>[LRHI9B H&22>!0 M9&J> M*="T5"VH:I:PX."ID!8?@.:\3^)_QHN#=3Z+X;E"1+\LMVO5CZ+[>]>0Z?H^ MN^*;P_9+:[OIF/S2'+<^[&@#ZN_X6QX(SC^WHO\ OV_^%;VE^)-&UI0=.U*V MG)Z*KC=^76OEMO@MXZ6#S3I ]=HGCSC_ +ZKE;FRUSPO?XFCO-/N%/##] 'W'17AOPI^,4NIW4.@^(I%\]_E@NSQN/]UO\ &OHWDVD>';AH+*,E)+B,X:4^Q[#Z4 >[ZIXP\/:-_Q_ZO:Q$<%0 M^XC\!DUCCXL>"&8*-=BR3@?NW_PKY:T3PCXD\7SL^G6-Q=L?O3.< _\ FX/ MYUOW/P6\<6T+2G2@X7DA9D)_G0!]4Z;KNE:Q&'T_4+>X![)("?RZUH5\.?\ M$\\+:A_R^:=U!(4 M$D@ (S=LUG:-B%3AV'\1_P *TITW4=D1.:@KLA\2>(6U"0VULQ%L MIY(_CKG***]2$%!61PRDY.["BBBK)"BBB@ HHHH ***M6%A/J-TMO N6;J>P MI-I*[&E?1#M-TV?4[M8(5/\ M-V45Z;INFP:9:+!"HX^\W=C4>DZ5#I5HL48 MRY^^_^\;R,2MG"%7^^_6L:3Q+JT MC9-VP]@H_P *R:*[HT81V1S.I)]38A\4:M"V?M);4@X2Y M6=L9*2N@HHHJ"@HHHH **** "BBB@ HHHH **** "OGC]H.]UZ34+6S-M-'H MT:[A(HRDC_[1'3'8&OH>H+RRM=0MGMKRWCGA<89)%R* /G'X.?"Z/7F&OZU" M6L$;$$+<"4CN?8'^5?2,$$-M"L4$211J,*B* !^%,LK*VTZSBM+.%8;>(;4C M7HHJ>@ KB/B1X$T[Q;X>N6:!(]0A0R0SJN&R!G!]U$#_G MZE_]"-?9O@LY\%Z03_S[+0!NU\_?M*?\?/AS_*6>J7]G;7%I:7$D<=T DJQG!<9Z5[7\,_@HMQ%!K7B9#L8!HK,G&1Z MMW_"L#X#>&M.USQ/=7>H1>=]AC$D4;?=+9QD_2OJ 8 P!0!!:65K80+!:6 M\4$2C 6- H_2IR 1@C(-%% 'SQ\?_!UI826GB&QA2$3MY4Z1K@%L<-BL+X!Z MN]CX[:R+$0WD!4KZL#\O\S7K?QT@23X77\K#+12PE3Z9D4?UKP3X2L1\3=%P M<9FP: /L2BBB@#YG_:(_Y'&Q_P"O;^HKI?VK M=^../6OEWP;X1OO&?B=-,CWH2VZXE8?ZL9Y)]Z^TR 1@C(-4+31=,L+V>]M+ M*&&XG $LB+@MB@"IX:\*Z5X5TN*QTVV1 BX:3'SN?4FMJBB@"IJ.F66K6!C:3N7DL)/+!/]T_='Z5ZC7B7[.'_ " M M:_Z[Q_R:O;: ,/QC_P B=JW_ %[/_*OBFRN/LE]!<%=WE2!\>N#7VMXQ_P"1 M.U;_ *]G_E7Q%0!W/AW0M6^*OC:5YG8*Y\RYGQQ&OH/Z"OJ#PYX*T'PO91V^ MG:?$K*!NE==SL?7)_I7/?![PLOAOP/;O)'MO+T":4D4CZ$_CR*]7KY"^,&N'6_B)J!5R8;4B",9Z;1AOUS M0!3^'7@F?QQXD6T)=+.+]Y)_"FE>+-*EL=3MU<,I M"2 ?/&>Q!]JVZ* /B+Q)H=YX/\47&G3%EFMI,QR#C<.Q%?5WPS\3GQ7X(L;Z M5@;E%\F?U++QD_7&?QKR[]HS18UETK68T^=PT,K>PP5_FU/_ &<-3$-!?Q-XJT_25SB>4 M;\?W!RWZ U]'_'N)Y?AH^Q<[+N)V]@ U> _#37(/#OQ TK4;H@0JYC8GH-ZE M<_AF@#[ TK2[/1M.AL;&%(H8E"@*,9]S[U=ID4B31++&P9'&58'@BGT 8'BG MP=H_B[39+34;9&8CY)E&'0^H-?*_B'X=Z[H'C!=#M[>:XFD;-K)&I^=<\-D= M,=_2OL>F&&)IEF:)#*HPKE1N ]C0!C>$+35K#PK86NMRI+?Q1[9'7OZ9]^U; ME%% !1110 4444 %%%% !1110 4444 %%%% !1T&:*X[Q/XD"AK&S?YNDD@_ MD*NG3QZ?9R7,I M^5!G'J?2K-<5XWOR9(;)#P!O>LJ4.>:1LUX[#_KX_\ >'\Z]?B_U*?[ MHKAQBU3.K#O1H?1117$=(4444 %%%% !1110 4444 %%%% !117*>.?'FF>! M]+%Q>-YES+D06ZGYG/K]/>@#IYIXK:%IIY$CC499W. /QKS[Q%\:?">A,\45 MR;^X4XV6_*G_ (%R*^>/%OQ%\0>+[IVO+MH[;=E+:([54?UJWX9^%/BGQ0B3 MP61M[5N?.N/E!'J,]: .PUK]H?6+G?'I.GV]K&W1Y=)M55]:OYKN4<[8<(GXYS_ #KT"Q\!>%]#MG:P MT:VC=8S\Y&XGCWH ^,7+,[,Y)8G))ZYK[:\%_P#(EZ1_U[+7QCK0 U[40!@" MZDP!_O&OL[P7_P B7I'_ %[+0!NU\_?M*?\ 'SX<_P!RX_G'7T#7S]^TI_Q\ M^'/]RX_G'0!#^S?_ ,A?6O\ K@O_ *%7T/7SQ^S?_P A?6O^N"_^A5]#T %% M%% 'G?QP_P"24:I_UT@_]&K7S]\)_P#DINB?]=Z^@?CA_P DHU3_ *Z0?^C5 MKY^^$_\ R4W1/^N] 'V+1110!\S_ +1'_(XV/_7M_45TO[./_(-UC_KHG]:Y MK]HC_D<;'_KV_J*Z7]G'_D&ZQ_UT3^M 'N=%%% !15:_O[;3+":]O)EAMX5W M.[' KYM^('QLU'6Y9=/T%FL[ 94RC[\O^ H ]T\1_$'PUX6##4M2C$RG!AC M.]P?=1R*\MUS]HM%W)HFD[B#Q+L>'_P!G:ZDV2Z]J2Q*?O06XRW_?7(_2@#BM7^,OC/568+J/V.-NL=N@ M _7)KBM0U*]U2X^T7]S+<2XP'D.3BOK31OA!X.T<*5TP74B])+AMS#\L"O'O MVA+2WL_&&EQ6T$<,8TY?E10!_K'H Z_]G#_D!:U_UWC_ )-7MM>)?LX?\@+6 MO^N\?\FKVV@##\8_\B=JW_7L_P#*OBW2XDGU6TBD&Y'E56'J,U]I>,?^1.U; M_KV?^5?&&B_\ANQ_Z[I_.@#[FME"VL*J, ( /I4M1P?\>\?^X/Y5)0!#=2> M39SR@XV1LV?H*^&M:N#=Z[J%RQR9KF20GURQ-?<&J?\ ((O?^N#_ /H)KX5G M_P"/B3_?/\Z /IS0_C-X$TG0K*P^W7/[B)4.+1\9K0_X7MX$_P"?ZZ_\!7_P MKSV#]G*^GMXIAXCM@)$#8^RMQD9_O5)_PS9?_P#0R6W_ ("M_P#%4 =]_P + MV\"?\_UU_P" K_X4?\+V\"?\_P!=?^ K_P"%<#_PS9?_ /0R6W_@*W_Q5'_# M-E__ -#);?\ @*W_ ,50 ?%SXE>%?%_A!+#2;B:6\2Y20;X&0!0#GD_A6-^S M["/$JZM-K M$-VHC9/+2 J>1CKDT >D:_HUMXAT.[TJ[&8;B,H3W'O7QSXO\'ZGX-UF2POX MSM!_=3@?+(O8@U]L5F:WX?TOQ%8M9ZI9QW$3#^(U_PFJ6KN M+ZP7@0S=5'^R?\:]R\,_&?PKXAV137']G7+=8[DX4?\ N!7 ^*OV>[A&DN/ M#=X)$ZBVN" W_?7 _2O']:\,ZUX^(O"\P?3]0D\O/S0R'IT444 %%%% !1110 4444 %%%% !1110 445S7B7Q$MC&U MI:MFX8?,1_ /\:J$'-V1,I**NR'Q/XC%LK65H_[X\.X_A]OK7#$EB23DGJ:& M9G8LQ)8G))I*]6G35-61PSFYN["BBBM" HHHH **** "BBG(C2.J(I9F. !W MH 6*)YY5BC4L[' KT;P]H":5 )90&N7'S'^[[5%X<\/+IT0N+A0;EA_WS70 MUYV(K\WNQV.RE2Y=7N%%%%6:_.;C7+ISV?:/PXKU.O)=34KJET#U\UO MYUUX->\SGQ&R*E%%%>@<@4444 %%%% %O2["M.,EQ)?. M/E0;4]SWKN:\[%3O.W8[*$;1N%%%%@ KXM\;^*+GQ=XIN]2F9O+9RL"$_<3L*^L?B'(T7P[\ M0.A(9;&4@CM\IKX^\/0K<^)=,AD&5>ZC# ]QN% 'OGPE^$MI9:?;Z_KL FO) M@)8(7'RQ+V)'<]_QKVE45%"HH51T & *2.-8HDC0!40!5 [ 4Z@ J*Y_X]9O M]QOY5+534[J"RTRYN+F18X8XV+.QP!Q0!\0:W_R']2_Z^I?_ $(U]F^"_P#D M2](_Z]EKXOU65)]8OIHVW1R7$C*?4%B17VAX+_Y$O2/^O9: -VOG[]I3_CY\ M.?[EQ_..OH&OG[]I3_CY\.?[EQ_..@"']F__ )"^M?\ 7!?_ $*OH>OGC]F_ M_D+ZU_UP7_T*OH>@ HHHH \[^.'_ "2C5/\ KI!_Z-6OG[X3_P#)3=$_Z[U] M _'#_DE&J?\ 72#_ -&K7S]\)_\ DINB?]=Z /L6BBB@#YG_ &B/^1QL?^O; M^HKI?VL[XJ7$ES\2M;,A)V7+1CZ D"OH3X):?%9?#2PEC"[KIGFG6L=O!&,*B#%7:** "OFG]HW_D=M,_[!P_]&/7TM7R]^T!J M5GJ'CJUCM9TE:ULQ#,%.=K[V;'Y$4 =I^SA_R M:_P"N\?\ )J]MKQ+]G#_D M!:U_UWC_ )-7MM &'XQ_Y$[5O^O9_P"5?&&B_P#(;L?^NZ?SK[/\8_\ (G:M M_P!>S_RKXPT7_D-V/_7=/YT ?<\'_'O'_N#^525'!_Q[Q_[@_E4E $%]'YMA M6Y&#%.Z'\&(K[NKXY^*FB-H7Q"U2';^[FD\]#CKO M^8_J30!]5>#;L7W@[2;E>1);*1S6Y7F'P*UY=5\!)9,^9["3RBOHA^[_ "-> MGT %%%% !17/^-/%%OX0\,W.K3@,T>%BC)QO<]!_.L+P'\5-'\;E;1%:UU+: M2UNYSG'7:>_Y4 =[13))$AB:21@J*,LQ/ %5=*U>PUNR%YIMU',I?%/A+R+R3??6+>4['JRX^4_P Q^%>D5\[_ +-TD@U?78PI M,9AB+'^[RU?1% !1110 4444 %%%% !1110 4450UJ]?3]+FN(QEU&%II-NR M$W97,_Q'X@73(3! 0;IA_P!\CUKSN21Y9&D=BS,](****XSH"BBB@ KS?Q99&UUJ1P,), Z_U_6O2*R=?T@:M8%%P)DYC)]?2 MMJ%3DG=F=6'-'0\PHJ2>"6VE:*9"CJ<$&HZ]0X0HHHIB"K>G:?-J5XEO".6/ M)]!ZT_3=)N]3G"01G;GYG/05Z+I&C6^D6^R(;I"/GD(Y-<]:LH*RW-:=)R=W ML6;&SCL+..WB&%0?F:LT45YK=W=G+=-DUCPAJVG1?ZRYM7B7ZD5\564[Z;JUO<8(>VG5\?[IS_2ONZOFOXQ M?"^ZTW4YO$&D0&6QN&+SQHO,+'OCTH ^@/#NMVWB'0;/4[6172>,,<=F[C\\ MUJ5\5>&/'/B'P=*W]E7C1H3EH)!N0GW6NMG^/?C.:%HT>SC)XW+#R/I0!]+: MUKVF>'M/DOM3ND@A09)8\GV ]:^8OB3\5;[QE.UC8E[?25/$8/,ONW^%*/'>J1I(]YJ=TQPBY+8]AZ5[9\.?@C!IJIJ?B54FN\9CMARL?N?4T ?./0X M-?;G@O\ Y$O2/^O9:^._%-F]EXLU:W*$;+N7 QVW''Z5]Q]* .IKY^_:4_P"/GPY_N7'\XZ^@:^?_ -I,$W/AS )^2X_G'0!!^S?_ M ,A?6O\ K@O_ *%7T/7SQ^S@"-7UK((_<+_Z%7T/0 4444 >=_'#_DE&J?\ M72#_ -&K7S]\)_\ DINB?]=Z^@?C@"?A3JF!_P M(/\ T:M?/_PG5O\ A9NB M<'_7^E 'V)1110!\T_M$QNOB[3W*D*]L=I]<&M[]G"YB-MK5MN'FAHW*^QS_ M (5L?'OPE<:SH5MK%G$TDU@2)%4<^6>N/QQ7S]X=\2ZKX3U5;_2YS#.O# CA MAZ$=Z /N&BOEN?X_^+Y(=D2V<3XP7\K/_P"JO0XZ?CFM[XM?#P^-=&2XL@!JEF"8L_\ +1>Z_P"?2OF"*35_"NLB1#/8W]NV M,C*L#0!]RTV21(D+R.%4=23@5\LP?'OQE# L;/9R,HQO:'D_6NIKT[P%\&=7\1SQ7FKHUCIGWOF'SR?0>GO5_XZ^&;/0+C0 MDTVV$-JEJ8%55[AF))]_FH ZO]G#_D!:U_UWC_DU>VUX#^SA>;'UJP(.7"2C MCTR/_9J]^H P_&/_ ")VK?\ 7L_\J^,-%_Y#=C_UW3^=?9_C'_D3M6_Z]G_E M7QEHJM_;=C\I_P!>G;WH ^Y8/^/>/_<'\JDJ.#_CWC_W!_*I* "O&_CWX.DU M;1X=?LXB]Q8KMF"CDQ]<_AG->R4R6))HGBE0/&X*LI'!!H ^//AKXWE\$>)5 MN7RUC./+N8_;L?J/ZU]=:7JMEK.GQ7UA<)/;RKN5E-?._P 3/@U>Z7=S:KX> M@,^GMEI(%^_$?8=Q7G.A>+?$/A*9AIM]/:Y.7B)(5OJ* /MJH+R]MM/M9+J[ MF2&&-2SNYP !7R^/C[XS$6TM8EL?>\C_ .O7)>(/&WB7Q>_EZC?33QDY$$>= M@/LM '0_%GXA-XSUL6UDS#2K4D1#_GHW=C7IOP&\%2:5IZK=PZMX@A:WL$(>.!A\TOU]!7TE'&D,2Q1J$C0!54#@ M4 >._'R7Q+#HL)L9"-&?Y;D1@[MW;TWQ%IT=]IETD\+]U/(/H:TJ^'=(UW6_"UZ9M.N[BRFZ,%)7=[$5W< M/Q\\91Q*CM9R$#&XP\F@#ZDFFCMXFEF=4C499F. *^2?B]XPA\6^,7:SD\RQ MLU,,#=F]2/8D5G^)/B7XJ\60FVOKXBW;K! NU6^H[UK_ ]^$^K>++R&ZO87 MM-)4[GE<8,@'910!Z9^SUX>EL/#]]K,R%#?.$0$=47H?S)_*O9JK6%C;Z980 M65I&(X($"(H'0"K- !1110 4444 %%%% !1110 4R6*.:-HY4#HPP589!I]% M &6?#NE$Y^QQ_P#?-'_".Z5_SYQ_E6I15^TEW)Y8]C+_ .$=TK_GSC_*C_A' M=*_Y\X_RK4HH]I+N'+'L9?\ PCNE?\^QECP[I0(/V.(X]5%7X+6" MU7;!"D:^B#%2T4G*3W8TDM@HHHJ1A1110 4444 %%%% &=J6B66J+^_CQ(.C MKU%!I@Q^SW*LO^V,5V]%:PK3AHF1*G&6Z."C\$7Q(\R:$#/."3_2M:R\ M%V<+!KF5IC_=Q@5T]%5+$5'U)5&"Z$<,$5O$(H8U1!T51@5)116!J%%%% !1 M110 4444 %%%% !1110 4444 %%%% !2, RE6&01@@TM% '%ZO\ "KP=K4YG MN-)CCD8Y9H/W98^IQ5"'X)^"(90XTZ1\=GE)'Y5Z'10!G:3H.E:%!Y.EZ?;V MB$8(AC"Y^N*T:** ,6Y\(>'+VY>XN=$L)II#EY'@4EC[FM.SLK73K5+:SMXX M($^['&NU1^%3T4 %9^IZ%I.LF,ZGIUM=F+.SSHPVW/7&?H*T** ,[3=!TC1F M=M-TVVM&D&',,87 ML^T\)^'K"Z2YM-%L8)XSE)(X5#+]#6S10 4444 (P#*589!&"#7#:O\ "'P9 MK-RUQ/IGDR,H]CVK&(I%DCT#3E=3E6%NN0?RK>HH 0 8' %+110 4 M444 %"-^[[!-USCSCBNAT M;P#X8T"19=/T>VCF4Y68Q@N/QKI** "BBB@ HHHH Y_6O!'AOQ 6?4M(M9I6 MZRF,;_SKFG^"'@AW+?8)AGLLQ KT6B@#DM)^&GA'1G\RVT6V:0'*R2H'9?H3 M76 # & *6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK$NO%>D67B*+0[BY$= M[+&9$5@<$#GKTKE]6^,?AS3KQ[:V2[U)HSB1K2(LJ'W)H ]#KG/'?B"X\+^$ M;W5K6-))H "JOT-2^&/&.C>+;0SZ5=+(R?ZR)N'0^X-87QA_Y)EJO^Z/YT = M#X1UB;7_ CI>K7"*DUW;K*ZKT!-;5><^%/%FB^%_A5X=FU6]CAS9)LCZLQ] M@.:32OC5X8U'4TLIOM-B9&VI)BD5@RAE(((R"*YSQ1XYT+P MBBC4KH"=_P#5P("SM^ _K0!TE%>;:?\ &KPY=7JV]Y!>Z<'.%DNHB%)_#->C M12QSQ)+$ZO&X#*RG((/>@!]%8%[XQT?3_$UMX?N)]E_<)O12#C'/?IVK.L?B M3H&J>+X_#>GS/SO MHC:+_K&8[=A]#FN/OOC?X5M+[R8_M5Q"&VME:K9:UIL- M_I\ZSVTPRKK4>LZYIOA_3WOM4NX[:W3^)NY] .IH T**\P/QQ\/+-S8ZC]FS MC[3Y/[O'K7?Z-KFF^(-/2_TNZ2YMWZ,O;Z@\B@#0HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@#P+XGZ/)X@^,^B:3%&YM65XY(XPI'/(X]JZ;X9?\DS\/?]>251^+__ "3/5O\ M<'\Z!&I\/KR6_P#A_H=U.Q:66U4LQ[FLVQ^'%DGC2_\ $>IS'4I9B/(CN%!$ M(] .E6?AFZQ_"_0'C^$9!8:5:R&*>]/\6.#S M_+'- ';?$*R\-W/A/4;:^.GQS"$F/<460,.F.]4?@CJ$]_\ #6R%PQ=H7>-6 M)YVAC@?@.*YB_P#@I8V>@7NH:OJ][J5Y%"S_ +R0E01Z=ZW/@+_R3>'_ *[R M?^A&@#BOBS9WNH_&72;+3Y#'$M 72VTY=)LU MMVC,9'DKG&,=<9S[UYGX-_Y.!\7?3^@KV:@#R3X&S20V6O:3G,%I?L8QZ \8 M_P#'174>+/ $'B[7M+O;^\D:RLV+-9?P.>Q^N?TKE/@I_P A'Q5_U^G^9J[X M_P#'NKP>((?"/A. 2ZO, 9)B 1"",]^,X]: .[NK+0+2R^SW<&G0VQ7;LE5% M7'XUY;\(I8;+XA>+M&TZ56TN.1Y(0C;E&' &#Z8-267P6OM5;[5XL\27EU,Y MW-#$_P GTP?Z53^$NEVVB_%;Q9IMHI6WMD>.,$YP!( * /<**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH \!^*.H7VE?&;1;_3;;[3=01;TAQG<-IW?IFO4O#_Q%\-Z M]IBW0U.VM9 ,2PW,HC9&[C#8KA/% !_:+\, C(,;9'_;-J[C5_ACX1UJ[:ZN M=)B$[G+O&S+N^H!Q0!Y[JEZOQ0^*VF6FF RZ/HQ,D]P!\K-D=#WY Q^-=M\8 M?^29:K_NC^==3HV@:5X>M!:Z38Q6L([(.3]2>34^I:99ZO8R66H6ZSVT@P\; M9P?RH Y_X9?\DS\/?]>251^+_P#R3/5O]P?SKL;&QMM,L8;*SA6&V@4)'&O1 M0.U,U'3;/5[&2ROX%GMI!AXVS@_E0!RG@*)Y_@]I,4?WY--*K]2"!7$_!'6] M,T/2]4T+5;J"RU""[;>+APF_'&:MZ/H6 MF>'[,VFE6B6L!;=L0DC/XF@#R?Q3_P G&>'?^N"?^S5[369/X>TFZUJ'6)[* M-]0@&V.'M)L]8N=6M[*.._N?]=."<5IT >0_!3_ )"/BK_K]/\ ,U1M+ZV\)?'S5)-;=8HM1@Q;7$O"KDAOO'@< M#%>MZ7H.EZ*]P^G6:6[7#[Y2I/SMZ\FJ^O\ A71/$\ BU?3XKD+]QFR"OT(H M QO$OQ+\.^'[+?'>PW]T_$-O:.)&=NP^7.*\\^#M[=ZC\3_%%Y?VQM;J>)I9 M("""A,BG&#S7I>B?#CPKH%P+BRTF(7 Z2N2Q_4XK8M= TJRU>YU6VLDCOKE= MLTP)RXSGGG'44 :5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 EX-101.SCH 4 atrs-20210302.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 atrs-20210302_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Document Period End Date Document Period End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 atrs-20210302_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 atrs-8k_20210302_htm.xml IDEA: XBRL DOCUMENT 0001016169 2021-03-02 2021-03-02 false 0001016169 8-K 2021-03-02 ANTARES PHARMA, INC. DE 1-32302 41-1350192 100 Princeton South Suite 300 Ewing NJ 08628 (609) 359-3020 false false false false Common Stock, par value $0.01 per share ATRS NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Mar. 02, 2021
Cover [Abstract]  
Entity Registrant Name ANTARES PHARMA, INC.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001016169
Document Period End Date Mar. 02, 2021
Entity Emerging Growth Company false
Entity File Number 1-32302
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 41-1350192
Entity Address, Address Line One 100 Princeton South
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Ewing
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08628
City Area Code (609)
Local Phone Number 359-3020
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ATRS
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports atrs-8k_20210302.htm atrs-20210302.xsd atrs-20210302_lab.xml atrs-20210302_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "atrs-8k_20210302.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "atrs-8k_20210302.htm" ] }, "labelLink": { "local": [ "atrs-20210302_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "atrs-20210302_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "atrs-20210302.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atrs", "nsuri": "http://www.antarespharma.com/20210302", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "atrs-8k_20210302.htm", "contextRef": "C_0001016169_20210302_20210302", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "atrs-8k_20210302.htm", "contextRef": "C_0001016169_20210302_20210302", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.antarespharma.com/20210302/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-010039-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-010039-xbrl.zip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